These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29992679)

  • 1. Benefits of combining change-point analysis with disproportionality analysis in pharmacovigilance signal detection.
    Trinh NTH; Solé E; Benkebil M
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):370-376. PubMed ID: 29992679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area.
    Grundmark B; Holmberg L; Garmo H; Zethelius B
    Eur J Clin Pharmacol; 2014 May; 70(5):627-35. PubMed ID: 24599513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
    Alvarez Y; Hidalgo A; Maignen F; Slattery J
    Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
    Alkabbani W; Gamble JM
    Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
    Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
    Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of pharmacovigilance signals with automated methods based on false discovery rates: a comparative study.
    Ahmed I; Thiessard F; Miremont-Salamé G; Haramburu F; Kreft-Jais C; Bégaud B; Tubert-Bitter P
    Drug Saf; 2012 Jun; 35(6):495-506. PubMed ID: 22612853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
    Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.
    Weill A; Païta M; Tuppin P; Fagot JP; Neumann A; Simon D; Ricordeau P; Montastruc JL; Allemand H
    Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1256-62. PubMed ID: 20945504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple method for exploring adverse drug events in patients with different primary diseases using spontaneous reporting system.
    Noguchi Y; Ueno A; Otsubo M; Katsuno H; Sugita I; Kanematsu Y; Yoshida A; Esaki H; Tachi T; Teramachi H
    BMC Bioinformatics; 2018 Apr; 19(1):124. PubMed ID: 29621976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benfluorex: increasing reports of valve disorders.
    Prescrire Int; 2010 Feb; 19(105):17. PubMed ID: 20455335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractures Related to Tenofovir: A Case/Noncase Study in the European Pharmacovigilance Database.
    García MG; Larrinaga-Torrontegui U; Eduardo Martinez E; Lertxundi U; Palacios-Zabalza I; Aguirre C
    Am J Ther; 2019; 26(5):e589-e592. PubMed ID: 29324463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Masking by vaccines in pediatric drug safety signal detection in the EudraVigilance database.
    Dodd C; Pacurariu A; Osokogu OU; Weibel D; Ferrajolo C; Vo DH; Becker B; Kors JA; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1249-1256. PubMed ID: 30066460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
    Scholl JH; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
    Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase.
    Roselli A; Khouri C; Roustit M; Blaise S; Cracowski JL
    Dermatol Surg; 2019 Dec; 45(12):1517-1528. PubMed ID: 30829775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Paediatric Pharmacovigilance at the European Medicines Agency: A Novel Query Applied to Adverse Drug Reaction Reports.
    Blake KV; Saint-Raymond A; Zaccaria C; Domergue F; Pelle B; Slattery J
    Paediatr Drugs; 2016 Feb; 18(1):55-63. PubMed ID: 26597489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.